Additional file 2 of Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

Supplementary Material 2: Supplementary Table 1. Cell line information. Supplementary Table 2. List of antibodies. Supplementary Table 3. KRAS dependency data. Supplementary Table 4. DeltaCT values of target genes normalized to GAPDH in HCT116 cells treated with or without TAK-981. Supplementary Table 5. Fold-change in target gene expression after TAK-981 treatment in HCT 116 cells. Supplementary Table 6. Normalized Z-scores of significant DEGs in HCT116 cells treated with TAK-981. Supplementary Table 7. MYC mRNA expression compared to that in normal cell lines. Supplementary Table 8. Trametinib sensitivity data from the GDSC.